Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.

enVVeno Medical Corporation

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PUBLISHED ECONOMIC HEALTH STUDY SHOWS BOTH SHORT- AND LONG-TERM COST-EFFECTIVENESS OF REPLACEMENT VENOUS VALUE THERAPY VERSUS STANDARD-OF-CARE TREATMENTS FOR DEEP VENOUS CVI, GENERATING COMPELLING EVIDENCE THAT WILL BE USED TO SUPPORT FUTURE COVERAGE DETERMINATIONS AND REIMBURSEMENT POLICIES FOR ENVVENO MEDICAL'S ENVVE NON-SURGICAL REPLACEMENT VENOUS VALVE PUBLICATION HIGHLIGHTS: PEER-REVIEWED PUBLICATION IN THE JOURNAL OF VASCULAR SURGERY: VENOUS AND LYMPHATIC DISORDERS MORE THAN $32,000 PROJECTED HEALTHCARE SAVINGS PER PATIENT OVER FIVE YEARS APPROXIMATELY 2.2 FEWER VENOUS ULCERS PER PATIENT COMPARED TO STANDARD OF CARE APPROXIMATELY $4,100 PROJECTED COST SAVINGS PER EACH RVCSS* POINT OF CLINICAL IMPROVEMENT ECONOMICALLY DOMINANT VERSUS COMPRESSION THERAPY AND WOUND CARE IN THE MODELED ANALYSIS APPROXIMATELY $5.9 BILLION ESTIMATED ANNUAL HEALTHCARE SAVINGS WITH BROADER ADOPTION OF EFFECTIVE VENOUS VALVE REPLACEMENT THERAPY *RVCSS (REVISED VENOUS CLINICAL SEVERITY SCORE) IS A VALIDATED CLINICAL TOOL USED TO EVALUATE DISEASE SEVERITY AND TREATMENT RESPONSE IN PATIENTS WITH CHRONIC VENOUS DISEASE. IRVINE, CA / ACCESS NEWSWIRE / AUGUST 4, 2026 / ENVVENO MEDICAL CORPORATION (NASDAQ:NVNO) ("ENVVENO MEDICAL" OR THE "COMPANY"), TODAY HIGHLIGHTED THE PUBLICATION OF A LANDMARK, PEER-REVIEWED HEALTH ECONOMIC ANALYSIS IN THE JOURNAL OF VASCULAR SURGERY: VENOUS AND LYMPHATIC DISORDERS DEMONSTRATING THE POTENTIAL CLINICAL AND ECONOMIC BENEFITS OF VENOUS VALVE REPLACEMENT THERAPY FOR PATIENTS WITH SEVERE DEEP VENOUS REFLUX.

INDEPENDENT HEALTH ECONOMIC STUDY RECENTLY PUBLISHED IN JOURNAL OF VASCULAR SURGERY REPORTS ECONOMIC DOMINANCE OF ENVVENO MEDICAL'S REPLACEMENT VENOUS VALVE THERAPY COMPARED TO STANDARD OF CARE TREATMENTS

COMPANY ENTERS THE SECOND HALF OF 2026 WITH TAILWINDS FROM AN FDA IDE APPROVAL, WITH THE TAVVE PIVOTAL STUDY EXPECTED TO BEGIN ENROLLING PATIENTS DURING THE SECOND HALF OF THIS YEAR AND CASH RUNWAY EXTENDING INTO THE THIRD QUARTER OF 2027 IRVINE, CA / ACCESS NEWSWIRE / JULY 31, 2026 / ENVVENO MEDICAL CORPORATION (NASDAQ:NVNO) ("ENVVENO MEDICAL" OR THE "COMPANY"), TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2026, AND HIGHLIGHTED BY THE SIGNIFICANT REGULATORY MILESTONE OF RECEIVING U.S. FOOD AND DRUG ADMINISTRATION (FDA) IDE APPROVAL TO BEGIN THE TAVVE PIVOTAL TRIAL FOR ITS ENVVE SYSTEM, A FIRST-IN-CLASS, MINIMALLY INVASIVE REPLACEMENT VENOUS VALVE FOR PATIENTS SUFFERING FROM SEVERE DEEP CHRONIC VENOUS INSUFFICIENCY (CVI). SECOND QUARTER 2026 HIGHLIGHTS ACHIEVED FIRST-EVER FDA IDE APPROVAL FOR A U.S. PIVOTAL STUDY EVALUATING A TRANSCATHETER REPLACEMENT VENOUS VALVE FOR SEVERE DEEP CVI.

ENVVENO MEDICAL REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND ADVANCES TOWARDS FDA PIVOTAL TRIAL FOR FIRST-IN-CLASS NON-SURGICAL REPLACEMENT VENOUS VALVE

CEO EXPLAINS HOW BROAD PATENT PROTECTION, COMBINED WITH FIRST-EVER FDA IDE APPROVAL, POSITIONS ENVVE TO OWN A MULTI-BILLION-DOLLAR VENOUS DISEASE MARKET WATCH THE "WHAT THIS MEANS" VIDEO HERE IRVINE, CA / ACCESS NEWSWIRE / JULY 15, 2026 / ENVVENO MEDICAL CORPORATION (NASDAQ:NVNO) ("ENVVENO MEDICAL" OR THE "COMPANY"), TODAY ANNOUNCED THAT ROBERT BERMAN, CHIEF EXECUTIVE OFFICER OF ENVVENO MEDICAL PARTICIPATED IN A VIRTUAL INVESTOR "WHAT THIS MEANS" SEGMENT. AS PART OF THE SEGMENT, MR.

ENVVENO MEDICAL HIGHLIGHTS NEWLY ISSUED U.S. PATENT STRENGTHENING COMPETITIVE POSITION AHEAD OF HISTORIC PIVOTAL TRIAL IN VIRTUAL INVESTOR "WHAT THIS MEANS" SEGMENT

NEW PATENT BROADLY PROTECTS CORE TECHNOLOGY BEHIND POTENTIAL FIRST NON-SURGICAL REPLACEMENT VENOUS VALVE BUILDS ON FIRST-EVER FDA IDE APPROVAL FOR PIVOTAL STUDY OF ENVVE SYSTEM TARGETING MULTI-BILLION-DOLLAR MARKET OPPORTUNITY ENVVE PIVOTAL STUDY ON TRACK FOR ENROLLMENT TO COMMENCE AND FIRST PATIENTS DATA RELEASE EXPECTED BY THE END OF Q4 2026 IRVINE, CA / ACCESS NEWSWIRE / JULY 7, 2026 / ENVVENO MEDICAL CORPORATION (NASDAQ:NVNO) ("ENVVENO MEDICAL" OR THE "COMPANY") TODAY ANNOUNCED THE ISSUANCE OF U.S. PATENT NO. 12,575,932, FURTHER EXPANDING ITS INTELLECTUAL PROPERTY PORTFOLIO SUPPORTING ITS ENVVE TRANSCATHETER REPLACEMENT VENOUS VALVE SYSTEM FOR THE TREATMENT OF VENOUS DISEASE.

ENVVENO MEDICAL SECURES TRANSFORMATIONAL U.S. PATENT FOR ENVVE SYSTEM, STRENGTHENING COMPETITIVE MOAT AHEAD OF LAUNCH OF HISTORIC FDA PIVOTAL TRIAL

- LIVE WEBCAST ON WEDNESDAY, JUNE 24TH AT 2:00 PM ET - ACCESS THE EVENT HERE IRVINE, CA / ACCESS NEWSWIRE / JUNE 22, 2026 / ENVVENO MEDICAL CORPORATION (NASDAQ:NVNO) ("ENVVENO" OR THE "COMPANY"),A COMPANY SETTING NEW STANDARDS OF CARE FOR THE TREATMENT OF DEEP VENOUS DISEASE, TODAY ANNOUNCED THAT IT WILL PRESENT IN THE WEBULL CORPORATE CONNECT WEBINAR SERIES BEING HELD VIRTUALLY JUNE 24-25, 2026. AS PART OF THE DISCUSSION, THE COMPANY'S CEO, ROB BERMAN, WILL PROVIDE AN OVERVIEW OF ENVVENO MEDICAL'S MISSION TO TRANSFORM THE TREATMENT OF DEEP VENOUS DISEASE, DISCUSS THE SIGNIFICANT UNMET NEED FOR PATIENTS SUFFERING FROM SEVERE DEEP VENOUS INSUFFICIENCY (DVI), REVIEW THE RECENT FDA IDE APPROVAL FOR THE COMPANY'S ENVVE SYSTEM, AND OUTLINE PLANS FOR ADVANCING THE FIRST-EVER U.S. PIVOTAL TRIAL OF A NON-SURGICAL REPLACEMENT VENOUS VALVE.

ENVVENO MEDICAL TO PRESENT IN THE WEBULL CORPORATE CONNECT WEBINAR SERIES

LIVE VIDEO WEBCAST WITH ROBERT BERMAN, CHIEF EXECUTIVE OFFICER OF ENVVENO MEDICAL, ON TUESDAY, JUNE 9THAT 4:00 PM ET REGISTER HERE IRVINE, CA / ACCESS NEWSWIRE / JUNE 2, 2026 / ENVVENO MEDICAL CORPORATION (NASDAQ:NVNO) ("ENVVENO" OR THE "COMPANY"), A COMPANY SETTING NEW STANDARDS OF CARE FOR THE TREATMENT OF DEEP VENOUS DISEASE, TODAY ANNOUNCED THAT ROBERT BERMAN, CHIEF EXECUTIVE OFFICER OF ENVVENO MEDICAL WILL PARTICIPATE IN A VIRTUAL INVESTOR CLOSING BELL EVENT ON TUESDAY, JUNE 9, 2026 AT 4:00 PM ET. AS PART OF THE EVENT, MR.

ENVVENO MEDICAL TO PARTICIPATE IN THE VIRTUAL INVESTOR CLOSING BELL SERIES

FIRST-EVER FDA IDE APPROVAL FOR A U.S. PIVOTAL STUDY OF A NON-SURGICAL REPLACEMENT VENOUS VALVE IDE APPROVAL POSITIONS ENVVENO TO ADVANCE WHAT COULD BECOME THE FIRST EFFECTIVE TREATMENT OPTION FOR THE APPROXIMATELY 3 MILLION U.S. PATIENTS SUFFERING FROM DVI WATCH THE "WHAT THIS MEANS" VIDEO HERE IRVINE, CA / ACCESS NEWSWIRE / MAY 12, 2026 / ENVVENO MEDICAL CORPORATION (NASDAQ:NVNO) ("ENVVENO MEDICAL" OR THE "COMPANY"), TODAY ANNOUNCED THAT ROBERT BERMAN, CHIEF EXECUTIVE OFFICER OF ENVVENO MEDICAL PARTICIPATED IN A VIRTUAL INVESTOR "WHAT THIS MEANS" SEGMENT. AS PART OF THE SEGMENT, MR.

ENVVENO MEDICAL DISCUSSES FDA IDE APPROVAL IN VIRTUAL INVESTOR "WHAT THIS MEANS" SEGMENT

COMPANY ENDED THE FIRST QUARTER WITH APPROXIMATELY $25 MILLION IN CASH AND INVESTMENTS CAPITAL ON HAND SHOULD FUND OPERATIONS THROUGH MULTIPLE KEY MILESTONES INTO Q3 2027 COMPANY RECENTLY RECEIVED FDA IDE APPROVAL TO COMMENCE TAVVE U.S. PIVOTAL STUDY FOR NON-SURGICAL REPLACEMENT VENOUS VALVE, ENVVE SYSTEM TAVVE SITE SELECTION IS UNDERWAY WITH PATIENT ENROLLMENT EXPECTED TO COMMENCE LATER THIS YEAR IRVINE, CA / ACCESS NEWSWIRE / MAY 7, 2026 / ENVVENO MEDICAL CORPORATION (NASDAQ:NVNO) ("ENVVENO MEDICAL" OR THE "COMPANY"), TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER 2026, ENDING THE QUARTER WITH APPROXIMATELY $25 MILLION IN CASH AND INVESTMENTS AND CONFIRMING THE COMPANY'S STRATEGIC FOCUS ON THE DEVELOPMENT OF ITS NEXT-GENERATION ENVVE SYSTEM FOR THE TREATMENT OF DEEP VENOUS INSUFFICIENCY. "WITH A STRONG BALANCE SHEET, SIGNIFICANT PHYSICIAN INTEREST IN THE ENVVE VALVE, AND A CLEARLY DEFINED REGULATORY PATHWAY, WE ARE WELL POSITIONED TO EXECUTE THE TAVVE STUDY AND ADVANCE THE COMPANY TOWARDS MULTIPLE NEAR-TERM AND LONG-TERM MILESTONES," SAID ROBERT BERMAN, CHIEF EXECUTIVE OFFICER OF ENVVENO MEDICAL.

ENVVENO MEDICAL REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE HIGHLIGHTING STRATEGIC ADVANCEMENT OF THE ENVVE SYSTEM

FIRST-IN-CLASS ENVVE SYSTEM TO BE EVALUATED IN TAVVE U.S. PIVOTAL TRIAL CLINICAL SITE ACTIVATION AND PATIENT ENROLLMENT EXPECTED TO COMMENCE LATER THIS YEAR LARGE UNMET CLINICAL NEED FOR APPROXIMATELY 3 MILLION U.S. PATIENTS WITH SEVERE DEEP CHRONIC VENOUS INSUFFICIENCY POTENTIAL MULTI-BILLION-DOLLAR UNTAPPED U.S. MARKET COMPANY HAS APPROXIMATELY $25 MILLION IN CASH AND INVESTMENTS TO FUND OPERATIONS INTO Q3 2027 IRVINE, CA / ACCESS NEWSWIRE / APRIL 29, 2026 / ENVVENO MEDICAL CORPORATION (NASDAQ:NVNO) ("ENVVENO" OR THE "COMPANY"), A COMPANY SETTING NEW STANDARDS OF CARE FOR THE TREATMENT OF DEEP VENOUS DISEASE, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS AWARDED THE COMPANY THE FIRST-EVER IDE APPROVAL TO PROCEED WITH A U.S. PIVOTAL STUDY OF A NON-SURGICAL REPLACEMENT VENOUS VALVE. THE TRANSCATHETER VENOUS VALVE ENDOPROSTHESIS (TAVVE) PIVOTAL STUDY WILL EVALUATE THE COMPANY'S MINIMALLY INVASIVE ENVVE SYSTEM FOR PATIENTS WITH SEVERE DEEP CHRONIC VENOUS INSUFFICIENCY (CVI).

ENVVENO MEDICAL RECEIVES FIRST-EVER FDA IDE APPROVAL FOR A U.S. PIVOTAL STUDY OF A NON-SURGICAL REPLACEMENT VENOUS VALVE

COMPANY ACCELERATED DEVELOPMENT OF THE ENVVE SYSTEM, COMPLETING PRE-CLINICAL STUDIES AND PROGRESSING TOWARD A 2026 PIVOTAL TRIAL INITIATION STRONG FINANCIAL POSITION EXPECTED TO PROVIDE AN OPERATING RUNWAY INTO MID-2027 THROUGH THE ACHIEVEMENT OF KEY CLINICAL MILESTONES IRVINE, CA / ACCESS NEWSWIRE / MARCH 27, 2026 / ENVVENO MEDICAL CORPORATION (NASDAQ:NVNO) ("ENVVENO MEDICAL" OR THE "COMPANY"), TODAY ANNOUNCED FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2025 AND PROVIDED A CORPORATE UPDATE HIGHLIGHTING ITS STRATEGIC FOCUS ON THE DEVELOPMENT OF ITS NEXT-GENERATION ENVVE SYSTEM. ROBERT BERMAN, CHIEF EXECUTIVE OFFICER OF ENVVENO MEDICAL CORPORATION, STATED, "2025 REPRESENTED A SIGNIFICANT INFLECTION POINT FOR THE COMPANY.

enVVeno Medical Corporation

NVNO

Price

Financial Reports

No items found.

Press Releases

enVVeno Medical Corporation

NVNO.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

NVNO